Bay State Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.

Press releases published on April 6, 2026

Netnumber Partners with TwoFive to bring Phone Number Intelligence Services to Japan and Vietnam
Modo Labs Named a Leader in the 2026 Gartner® Magic Quadrant™ for Workplace Experience Applications
New England Electropolishing Marks 40 Years as America's Premier Precision Stainless Steel Finishing Specialist
EPC Space Introduces High-Accuracy GaN Linear Regulator Evaluation Boards
PEO Claims Advocacy Programs Help Employees Navigate Insurance Denials and Billing Disputes
Lydonia Named to the Distinguished CRN Tech Elite 250 List for 2026
ImEx Cargo Launches Partner Platform Connecting Primes, DBEs, and Agencies
mEinstein Announces Launch of Mobile-Native Personal AI OS Focused on On-Device Intelligence
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Global Validation, Calibration and Standardization in Life Sciences Market to Reach $3.9 Billion by 2030, Fueled by Regulatory Demands and Digital Transformation
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Azurity Pharmaceuticals Announces the Availability of ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII
Paytronix 2026 Loyalty Report: Real-Time Personalization & AI-Powered Decisioning Drive Success
Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Nano Dimension Announces the Sale of AME and Fabrica Product Lines
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Bay State Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.